Interestingly, the antihypertrophic effects of metformin were not observed in AMPKα2–/– mice (71), suggesting that the chronic activation of AMPK during the development of cardiac hypertrophy is an important mechanism that mediates the beneficial effect of metformin. The gene discussed is PRKAA2; the disease is cardiac hypertrophy.